4D Molecular Therapeutics (FDMT) FCF Margin (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly FCF Margin of 2235.81% for Q1 2026, up 33989277.0% year-over-year from N/an in Q1 2025, and down 7951.62% quarter-over-quarter from 28.48% in Q4 2025.
4D Molecular Therapeutics (FDMT) FCF Margin (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported FCF Margin for 7 consecutive years, with 2235.81% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 33989277.0% year-over-year to 2235.81%; the TTM figure through Mar 2026 stood at 152.12% (up 68015657.0% YoY), while the FY2025 annual figure was 133.8%, up 37384188.0% from the prior year.
- FCF Margin eased to 2235.81% in Q1 2026 per FDMT's latest filing, from 28.48% in the prior quarter.
- Across five years, FCF Margin topped out at 119273.68% in Q4 2023 and bottomed at 4681200.0% in Q4 2024.
- Historically, FCF Margin has averaged 414527.6% across 5 years, with a median of 9704.03% in 2023.
- Annual changes were most pronounced in 2024 — FCF Margin sank 480047368 bps — and 2025, when it jumped 468122848 bps.
- 4D Molecular Therapeutics' FCF Margin stood at 1746.11% in 2022, then jumped by 6931 bps to 119273.68% in 2023, then tumbled by 4025 bps to 4681200.0% in 2024, then jumped by 100 bps to 28.48% in 2025, then slumped by 7952 bps to 2235.81% in 2026.
- Business Quant data shows FDMT's FCF Margin at 2235.81% in Q1 2026, 28.48% in Q4 2025, and 51563.33% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | -1,850.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,850.86% |
| Mar 31, 2026 | -2,235.81% |
| Dec 31, 2025 | 28.48% |
| Sep 30, 2025 | -51,563.33% |
| Jun 30, 2025 | -292,893.33% |
| Mar 31, 2025 | -342,128.57% |
| Dec 31, 2024 | -4,681,200.00% |
| Sep 30, 2024 | -1,038,966.67% |
| Jun 30, 2024 | -611,840.00% |
| Mar 31, 2024 | -106,421.43% |
| Dec 31, 2023 | 119,273.68% |
| Sep 30, 2023 | -15.25% |
| Jun 30, 2023 | -8,939.33% |
| Mar 31, 2023 | -9,704.03% |
| Dec 31, 2022 | -1,746.11% |
| Sep 30, 2022 | -2,597.80% |
| Jun 30, 2022 | -13,561.73% |
| Mar 31, 2022 | -2,458.00% |
| Dec 31, 2021 | -29,273.91% |
| Sep 30, 2021 | -1,419.33% |